Q30 Innovations careers

Unlike other proposed solutions, extensive clinical studies have been performed on the Q-Collar. Q30 expects to receive FDA approval in 2020. Q30 successfully completed its phase 3 FDA pivotal study involving 450+ high school football and girls soccer players for the fall sports season.

Data collection and analysis of 1,500+ MRI scans of athletes pre-, during- and post-season over four years have demonstrated that subjects who wear the Q-Collar show virtually no change in brain structure and function versus a non-collar wearing control group that experience significant negative changes over the course of a season. Exposure to over 500,000 impacts to the head of 20g force or greater during studies.

The Q-Collar has been approved as a Class 1 medical device in Canada and is approved for use in Australia and New Zealand. Approval as a class 1 device in Europe should be secured in late 2019.